User profiles for Miles W. Carroll
 | Miles CarrollPorton Down, Public Health England Verified email at phe.gov.uk Cited by 40235 |
Animal models for COVID-19
…, RA Albrecht, H Andersen, RS Baric, MW Carroll… - Nature, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of
coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the …
coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the …
Advances and gaps in SARS-CoV-2 infection models
…, L Widerspick, RA Albrecht, M Beer, MW Carroll… - PLoS …, 2022 - journals.plos.org
The global response to Coronavirus Disease 2019 (COVID-19) is now facing new challenges
such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern (VOCs). …
such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern (VOCs). …
Real-time, portable genome sequencing for Ebola surveillance
…, A Rambaut, P Formenty, S Günther, MW Carroll - Nature, 2016 - nature.com
The Ebola virus disease epidemic in West Africa is the largest on record, responsible for over
28,599 cases and more than 11,299 deaths 1 . Genome sequencing in viral outbreaks is …
28,599 cases and more than 11,299 deaths 1 . Genome sequencing in viral outbreaks is …
Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa
West Africa is currently witnessing the most extensive Ebola virus (EBOV) outbreak so far
recorded 1 , 2 , 3 . Until now, there have been 27,013 reported cases and 11,134 deaths. The …
recorded 1 , 2 , 3 . Until now, there have been 27,013 reported cases and 11,134 deaths. The …
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
…, S Camara, M Cao, F Cappuccini, M Carr, MW Carroll… - The Lancet, 2020 - thelancet.com
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …
was announced, containing far more mutations in Spike (S) than previously reported …
[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …
…, S Camara, M Cao, F Cappuccini, M Carr, MW Carroll… - The Lancet, 2020 - thelancet.com
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …
death if they develop COVID-19 and are therefore a priority for immunisation should an …
[HTML][HTML] Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
began when the first sequence was published, and this forms the basis for …
began when the first sequence was published, and this forms the basis for …
An introduction to the Marburg virus vaccine consortium, MARVAC
…, S Becker, K Bok, D Boucher, MW Carroll… - PLoS …, 2022 - journals.plos.org
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the
MARV vaccine “MARVAC” consortium representing leaders in the field of vaccine research …
MARV vaccine “MARVAC” consortium representing leaders in the field of vaccine research …
[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
change, with variants conferring advantage rapidly becoming dominant lineages, eg, B.…
